(12) STANDARD PATENT (11) Application No. **AU 2009275869 B2**
(19) AUSTRALIAN PATENT OFFICE

(54) Title
Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases

(51) International Patent Classification(s)
G01N 33/68 (2006.01)

(21) Application No: **2009275869** (22) Date of Filing: **2009.07.31**

(87) WIPO No: **WO10/012828**

(30) Priority Data

(31) Number	(32) Date	(33) Country
61/085,154	**2008.07.31**	**US**

(43) Publication Date: **2010.02.04**
(44) Accepted Journal Date: **2015.05.21**

(71) Applicant(s)
Probiodrug AG

(72) Inventor(s)
Demuth, Hans-Ulrich;Schilling, Stephan;Kleinschmidt, Martin;Rahfeld, Jens-Ulrich;Kehlen, Astrid;Bornack, Monique

(74) Agent / Attorney
Watermark Patent and Trade Marks Attorneys, Level 2 302 Burwood Road, HAWTHORN, VIC, 3122

(56) Related Art
WO 2008/034891

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 February 2010 (04.02.2010)

PCT

(10) International Publication Number
WO 2010/012828 A3

(51) International Patent Classification:
G01N 33/68 (2006.01)

(21) International Application Number:
PCT/EP2009/059951

(22) International Filing Date:
31 July 2009 (31.07.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/085,154 31 July 2008 (31.07.2008) US

(71) Applicant *(for all designated States except US)*: **PROBIODRUG AG** [DE/DE]; Weinbergweg 22, 06120 Halle/Saale (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DEMUTH, Hans-Ulrich** [DE/DE]; Am Waldrand 13a, 06120 Halle / Saale (DE). **SCHILLING, Stephan** [DE/DE]; Glockenweg 4, 06130 Halle / Saale (DE). **KLEINSCHMIDT, Martin** [DE/DE]; Ludwig-Wuchcrer-Strasse 13, 06120 Halle / Saale (DE). **RAHFELD, Jens-Ulrich** [DE/DE]; Mittelstrasse 23, 06120 Lieskau (DE). **KEHLEN, Astrid** [DE/DE]; Ballenstedter Strasse 8, 06124 Halle/Saale (DE). **BORNACK, Monique** [DE/DE]; Kasseler Strasse 13, 04155 Leipzig (DE).

(74) Agent: **HOFFMANN, Matthias**; Probiodrug AG, Weinbergweg 22, 06120 Halle / Saale (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
6 May 2010

WO 2010/012828 A3

(54) Title: GLUTAMINYL CYCLASE AS A DIAGNOSTIC / PROGNOSTIC INDICATOR FOR NEURODEGENERATIVE DISEASES

(57) Abstract: The present invention relates to a method for predicting, diagnosing and prognosticating a neurodegenerative disease, such as Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and neurodegeneration in Down's syndrome (NDS) using glutaminyl cyclase (QC) as a diagnostic/prognostic indicator. The use of antibodies binding to QC and kits for performing said diagnostic method are also provided.

Glutaminyl cyclase as a diagnostic/prognostic indicator for neurodegenerative diseases

FIELD OF THE INVENTION

The present invention relates to a method for predicting, diagnosing and prognosticating a neurodegenerative disease, such as Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and neurodegeneration in Down's syndrome (NDS) using glutaminyl cyclase (QC) as a diagnostic/prognostic indicator.

BACKGROUND OF THE INVENTION

Alzheimer Disease (AD) is a neurodegenerative disease that causes dementia. The terms "Alzheimer Disease" and "Alzheimer's Disease" are both utilized in the art, these terms being equivalent and are used interchangeably here and elsewhere. The period from first detection of AD to termination can range from a few years to 15 years, during which time the patient progressively suffers loss of both mental function and control of bodily functions. There is significant variability in the progress of the disease. While the majority of patients have a gradual, inexorable progression (losing on average 3 to 4 points on the 30 point Folstein mini-mental state score annually) , approximately 30% of AD cases have a prolonged stable initial plateau phase lasting several years (Haxby J. V., et al., Individual trajectories of cognitive decline in patients with dementia of the Alzheimer type, J. Clin. Exp. Neuropsychol 14:575-592, 1992.). A subgroup of patients has a fulminant, rapidly progressive downhill course over several years (Mann, U., et al., Heterogeneity in Alzheimer's disease: Progression rate segregated by distinct neuropsychological and cerebral metabolic profiles, J. Neurol. Neurosurg. Psychiatry 55:956-959, 1992). Other patients (about 10% of cohorts) remain slowly progressive, showing only gradual decline from year to year (Grossi, D., et al . , Senile dementias, II International Symposium (pp. 97-99), Paris: John Libbey Eurotext, 1988.). The pathological, chemical and molecular bases of this heterogeneity remain undetermined. Recognition of the variability of AD progression represents an important clinical insight, and may explain the diagnostic difficulties presented by "atypical" cases. While in certain cases, there is a familial manifestation of the AD disease, it appears that the majority of AD cases are non-familial, and until recently (see below), no simple biological marker for the disease had been determined.

Current methods used to diagnose AD involve analysis of cerebrospinal fluid (CSF) or brain tissue obtained from postmortem patients. Thus, among the markers currently under consideration are those related to the proteins, which account for the features found in Alzheimer

brains postmortem. The neurofibrillary tangle is composed primarily of a hyperphosphorylated tau protein, a cytoskeletal protein. The neuritic plaque contains a core of amyloid protein, much of which is a 42-amino acid peptide ($A\beta_{42}$) derived from proteolytic cleavage of a larger precursor protein. Another form of this protein derived from the same precursor contains only 40 amino acids ($A\beta_{40}$). Deposits of this protein are found in the brains of AD victims. However, alterations in tau and the aforementioned beta amyloid peptides do not occur with sufficient frequency and magnitude so as to afford diagnostic value and therefore, blood tests based on these proteins do not seem to correlate well with AD. In addition to C-terminal variability, N-terminally modified Aβ peptides are abundant (Saido, T.C. et al. Dominant and differential deposition of distinct beta-amyloid peptide species, Aβ N3(pE), in senile plaques. Neuron 14, 457-466 (1995) ; Russo, C. et al. Presenilin-1 mutations in Alzheimer's disease. Nature 405, 531-532 (2000); Saido, T.C., Yamao, H., Iwatsubo, T. & Kawashima, S. Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci. Lett. 215, 173-176 (1996)). It appears that a major proportion of the Aβ peptides undergoes N-terminal truncation by two amino acids, exposing a glutamate residue, which is subsequently cyclized into pyroglutamate (pE), resulting in Aβ3(pE)-42 peptides (Saido, T.C. et al. Dominant and differential deposition of distinct beta-amyloid peptide species, Aβ N3(pE), in senile plaques. Neuron 14, 457-466 (1995) ; Saido, T.C., Yamao, H., Iwatsubo, T. & Kawashima, S. Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci. Lett. 215, 173-176 (1996)). Alternatively, pE may be formed following β'-cleavage by BACE1, resulting in Aβ N11(pE)-42 (Naslund, J. et al. Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. Proc. Natl. Acad. Sci. U. S. A. 91, 8378-8382 (1994); Liu, K. et al. Characterization of Aβ11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease. Acta Neuropathol. 112, 163-174 (2006)). In particular Aβ N3(pE)-42 has been shown to be a major constituent of Aβ deposits in sporadic and familial AD (Saido, T.C. et al. Dominant and differential deposition of distinct beta-amyloid peptide species, Aβ N3(pE), in senile plaques. Neuron 14, 457-466 (1995) ; Miravalle, L. et al. Amino-terminally truncated Aβ peptide species are the main component of cotton wool plaques. Biochemistry 44, 10810-10821 (2005)).

The Aβ N3pE-42 peptides coexist with Aβ 1-40/1-42 peptides (Saido, T.C. *et al.* Dominant and differential deposition of distinct beta-amyloid peptide species, Abeta N3pE, in senile plaques.

Neuron 14, 457-466 (1995) ; Saido, T.C., Yamao, H., Iwatsubo, T. & Kawashima, S. Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. *Neurosci. Lett.* 215, 173-176 (1996)), and, based on a number of observations, could play a prominent role in the pathogenesis of AD. For example, a particular neurotoxicity of Aβ N3pE-42 peptides has been outlined (Russo, C. *et al.* Pyroglutamate-modified amyloid beta-peptides--AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival. *J. Neurochem.* 82, 1480-1489 (2002) and the pE-modification of N-truncated Aβ peptides confers resistance to degradation by most aminopeptidases as well as Aβ-degrading endopeptidases (Russo, C. *et al.* Pyroglutamate-modified amyloid beta-peptides--AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival. *J. Neurochem.* 82, 1480-1489 (2002); Saido, T.C. Alzheimer's disease as proteolytic disorders: anabolism and catabolism of beta-amyloid. *Neurobiol. Aging* 19, S69-S75 (1998)). The cyclization of glutamic acid into pE leads to a loss of N-terminal charge resulting in accelerated aggregation of Aβ N3pE compared to the unmodified Aβ peptides (He, W. & Barrow, C.J. The Aβ 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length Aβ. *Biochemistry* 38, 10871-10877 (1999); Schilling, S. *et al.* On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). *Biochemistry* 45, 12393-12399 (2006)). Thus, reduction of Aβ N3pE-42 formation should destabilize the peptides by making them more accessible to degradation and would, in turn, prevent the formation of higher molecular weight Aβ aggregates and enhance neuronal survival.

However, for a long time it was not known how the pE-modification of Aβ peptides occurs. The present Applicant discovered that glutaminyl cyclase (QC) is capable to catalyze Aβ N3pE-42 formation under mildly acidic conditions, that specific QC inhibitors prevent Aβ N3pE-42 generation *in vitro* and that, therefore, inhibition of glutaminyl cyclase is a novel therapeutic concept for the causative treatment of Alzheimer's disease (Schilling, S., Hoffmann, T., Manhart, S., Hoffmann, M. & Demuth, H.-U. Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. *FEBS Lett.* 563, 191-196 (2004) ; Cynis, H. *et al.* Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells. *Biochim. Biophys. Acta* 1764, 1618-1625 (2006); Schilling *et al.* Inhibition of glutaminyl cyclase – a novel therapeutic concept for the causative treatment of Alzheimer's disease. *Nature Medicine* 14, 1106-1111 (2008)).

At present, there appears to be no satisfactory- diagnostic marker for existing AD, or for a subject, who although exhibiting normal cognitive responses, will inevitably, or most likely, develop AD.

Age-Associated Cognitive Decline (AACD) and Mild Cognitive Impairment (MCI) are terms used to identify individuals who experience a cognitive decline that falls short of dementia. These terms are equivalent, MCI being a more recently adopted term, and are used interchangeably throughout this application. Satisfaction of criteria (World Health Organization) for this diagnosis requires a report by the individual or family of a decline in cognitive function, which is gradual, and present at least 6 months. There may be difficulties across any cognitive domains (although memory is impaired in the vast majority of cases) , and these must be supported by abnormal performance on quantitative cognitive assessments for which age and education norms are available for relatively healthy individuals (i.e., the patient is compared to normal subjects his/her own age) . Performance must be at least 1 SD below the mean value for the appropriate population on such tests. Neither dementia, nor significant depression or drug effects may be present. No cerebral or systemic disease or condition known to cause cerebral cognitive dysfunction may be present. In Applicant's experience, all patients who were classified as CDR.5 ("questionable dementia") on the Clinical Dementia rating scale and who met these exclusions, also met the criteria for AACD/MCI . About 1/3 of Alzheimer's patients have had a clearly definable period of isolated memory deficit which preceded their more global cognitive decline. (Haxby J. V., et al . , Individual trajectories of cognitive decline in patients with dementia of the Alzheimer type, J. Clin. Exp. Neuropsychology 14:575-592, 1992.) Using AACD/MCI criteria, which look at other domains in addition to memory, the percentage with an identifiable prodrome is likely higher. Fortunately, not all AACD/MCI individuals seem to decline. It appears that a significant number of these subjects show a stable, non-progressive memory deficit on testing.

Attempts at predicting the onset of AD, MCI or NDS, or monitoring their progression have met with limited success. It has been discovered by the inventors of this application that an amount of QC in a biological sample obtained from a subject that deviates from a reference amount in a control person can be positively correlated to a neurological disease state. Thus, the correlation of the presence of QC with the disease state represents a positive and more direct test for diagnosis in a patient suffering from one of the neurodegenerative diseases described above.

Accordingly, the invention provides an easily administered biological sample test for predicting, diagnosing, or prognosticating AD, MCI and NDS using QC as a diagnostic marker.

SUMMARY OF THE INVENTION

The present invention is based on the discovery that an amount of glutaminyl cyclase (QC) in a biological sample obtained from a subject suffering from AD or MCI is elevated compared to an amount of QC in the biological sample obtained from a normal (i.e. healthy) control subject.

The indication that the amount of QC differs between these neurological diseases and normal controls, forms the basis for the development of a test for diagnosing AD, MCI or NDS in a subject. As such, the methods for diagnosing AD, MCI or NDS of the present invention by measuring the amount of QC in patient sample will greatly improve current clinical diagnostic assessment for patients suffering from these neurodegenerative diseases.

Based on the newly discovered differences in the amount of QC present in a biological sample obtained from a patient compared to that of a normal control, a strong correlation of the amount of QC can be made to a probable diagnosis of a neurodegenerative disease. A statistically significant elevation in the amount of QC relative to control samples is reasonably predictive that the patient has AD, NDS or MCI. A normal amount of QC as determined by an amount of QC characteristic of a control QC sample isolated from a normal age-matched population indicates that the patient does not have a neurodegenerative disease, such as AD, MCI or NDS. A positive indication of a neurodegenerative disease based on an elevated or reduced amount of QC in a biological sample relative to a normal control is generally considered together with other factors in making a definitive determination of a particular disease. Therefore, the elevated or reduced QC levels of the subject being tested will usually be considered together with other accepted clinical symptoms of AD, MCI or NDS-related conditions in making a determinative diagnosis of a neurodegenerative disease.

Thus, according to a first aspect of the invention, there is provided a method for diagnosing probable Alzheimer's Disease (AD), Neurodegeneration in Down's syndrome (NDS) or Mild Cognitive Impairment (MCI) in a subject, the method comprising:

(a) detecting the amount of glutaminyl cyclase (QC), or its isoforms, in a biological sample obtained from said subject; and

(b) comparing the detected amount of QC in the biological sample with an amount of QC characteristic of a normal control;

whereby an elevated amount of QC in said biological sample relative to the normal control is a positive indicator of AD or MCI .

According to a preferred embodiment of the invention, the biological sample is a fluid body sample such as serum, plasma, urine or cerebrospinal fluid. More preferably, the fluid body sample is plasma.

According to a further embodiment of the present invention, the amount of QC is detected either on the basis of the QC protein level or the QC mRNA level.

The amount of QC detected or quantified in a biological sample from a subject can be accomplished by any means known in the art. Such means may include, but are not limited to, for example by immunoturbidimetric assay, immunofluorescence, immunodiffusion, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), Western Blot, protein activity assay or, for the determination of the QC mRNA level, Northern Blot or polymerase chain reaction (PCR) analysis, for example real-time PCR. Also useful are high performance liquid chromatography (HPLC) , mass spectrometry (MS) and gas chromatography (GC) , as well as their various configurations, including gas chromatograph-mass spectrometry (GC-MS) , liquid chromatography-mass spectrometry (LC-MS) and liquid-chromatography-tandem mass spectrometry (LC-MS/MS) systems.

Preferably, the amount of QC in the biological sample is detected using an antibody that binds to QC in an immunoassay format. Thus, according to a preferred embodiment of the invention, there is provided a method of diagnosing a neurodegenerative disease in a subject, the method comprising:

(a) obtaining a biological sample from said subject ;

(b) contacting said biological sample with an antibody that binds to glutaminyl cyclase (QC), or its isoforms ;

(c) allowing the antibody and QC to form an immune complex; and

(d) detecting the amount of immune complex formed as an indication of the amount of QC in said biological sample; and

(e) comparing the detected amount to a normal control;

whereby a detected amount that is elevated or reduced relative to the normal control is a positive indicator of a neurodegenerative disease.

According to yet a further aspect of the invention, there is provided a diagnostic kit for determining whether a subject is suffering from a neurodegenerative disease comprising an antibody that binds to QC and an established standard of an amount of QC characteristic of a normal control. Reagents and instructions for carrying out the assays may also be included.

SHORT DESCRIPTION OF THE FIGURES

Figure 1: Figure 1 (a) shows the analysis of QC transcript levels applying quantitative RT-PCR. Total RNA from human neocortical brain samples (Brodmann area 22) was isolated from normally aged and AD brains of different Braak stages as indicated. The QC transcript level was normalized to house-keeping transcript concentration. Figure 1 (b) shows the Western-Blot analysis for QC from the same cases and brain region as used for QC mRNA analysis. The extraction of soluble protein was normalized to the tissue weight. Figure 1 (c) shows the quantification of Aβ N3(pE)-42 (indicated as $A\beta_{3(pE)-42}$) and of Aβ 1-42 ($A\beta_{1-42}$) concentrations from the same cases and brain region applying ELISA analysis of SDS- and formic acid extracts of human neocortical brain samples. Note the robust increase in Aβ N3(pE)-42 peptide concentrations at early AD stages compared to the much more moderate increase in Aβ 1-42 peptides. Figure 1 (d) shows the immunohistochemical detection of total Aβ peptides by the antibody 4G8 and of Aβ N3(pE)-42 peptides in Brodmann area 22 from normally aged subjects and different AD stages. Sparse Aβ plaques were detected in normal aging but these deposits lacked Aβ N3(pE)-42 immunoreactivity. At all AD stages, however, the majority of Aβ plaques contains Aβ N3(pE)-42 peptides.

Figure 2 shows the results of the determination of the gene expression rate of QC and CCL2 in stimulated THP-1 cells.

Figure 3 shows the results of the determination of the specific QC activity in conditioned medium of THP-1 cells.

SEQUENCES OF AMYLOID PEPTIDES AND CHEMOKINES

Aβ(1-42) (SEQ ID NO: 6)	Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala
Aβ(1-40) (SEQ ID NO: 7)	Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val
Aβ(3-42) (SEQ ID NO: 8)	Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala
Aβ(3-40) (SEQ ID NO: 9)	Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val
Aβ(1-38) (SEQ ID NO: 10)	Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly
Aβ(3-38) (SEQ ID NO: 11)	Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly
ABri (SEQ ID NO: 12)	EASNCFAIRHFENKFAVETLICSRTVKKNIIEEN
ADan (SEQ ID NO: 13)	EASNCFAIRHFENKFAVETLICFNLFLNSQEKHY
CCL2 (small inducible cytokine A2) (SEQ ID NO: 14) Swiss-Prot: P13500	QPDAINAPVTCCYNFTNRKISVQRLASYRRITSSKCPKEAVIFKTI VAKEICADPKQKWVQDSMDHLDKQTQTPKT
CCL7 (Small-inducible cytokine A7) (SEQ ID NO: 15) Swiss-Prot: P80098	QPVGINTSTTCCYRFINKKIPKQRLESYRRTTSSHCPREAVIFKTK LDKEICADPTQKWVQDFMKHLDKKTQTPKL
CCL8 (small inducible cytokine A8) (SEQ ID NO: 16) Swiss-Prot: P80075	QPDSVSIPITCCFNVINRKIPIQRLESYTRITNIQCPKEAVIFKTKRG KEVCADPKE RWVRDSMKHLDQIFQNLKP
CCL9/10 (Small-inducible cytokine A9) (SEQ ID NO: 17) Swiss-Prot: P51670	QITHATETKEVQSSLKAQQGLEIEMFHMGFQDSSDCCLSYNSRIQ CSRFIGYFPTSGGCTRPGIIFISKRGFQVCANPSDRRVQRCIERLEQ NSQPRTYKQ

CCL13 (Small-inducible cytokine A13) (SEQ ID NO: 18) Swiss-Prot: Q99616	QPDALNVPSTCCFTFSSKKISLQRLKSYVITTSRCPQKAVIFRTKL GKEICADPKEKWVQNYMKHLGRKAHTLKT
CCL15 (Small-inducible cytokine A15) (SEQ ID NO: 19) Swiss-Prot: Q16663	QFINDAETELMMSKLPLENPVVLNSFHFAADCCTSYISQSIPCSLM KSYFETSSECSKPGVIFLTKKGRQVCAKPSGPGVQDCMKKLKPY SI
CCL16 (Small-inducible cytokine A16) (SEQ ID NO: 20) Swiss-Prot: O15467	QPKVPEWVNTPSTCCLKYYEKVLPRRLVVGYRKALNCHLPAIIF VTKRNREVCTNPNDDWVQEYIKDPNLPLLPTRNLSTVKIITAKNG QPQLLNSQ
Fractalkine (neurotactin) (SEQ ID NO: 21) Swiss-Prot: P78423	QHHGVTKCNITCSKMTSKIPVALLIHYQQNQASCGKRAIILETRQ HRLFCADPKEQWVKDAMQHLDRQAAALTRNGGTFEKQIGEVKP RTTPAAGGMDESVVLEPEATGESSSLEPTPSSQEAQRALGTSPEL PTGVTGSSGTRLPPTPKAQDGGPVGTELFRVPPVSTAATWQSSAP HQPGPSLWAEAKTSEAPSTQDPSTQASTASSPAPEENAPSEGQRV WGQGQSPRPENSLEREEMGPVPAHTDAFQDWGPGSMAHVSVVP VSSEGTPSREPVASGSWTPKAEEPIHATMDPQRLGVLITPVPDAQ AATRRQAVGLLAFLGLLFCLGVAMFTYQSLQGCPRKMAGEMAE GLRYIPRSCGSNSYVLVPV
CCL25 (Small-inducible cytokine A25) (SEQ ID NO: 22) Swiss-Prot: O15444	QGVFEDCCLAYHYPIGWAVLRRAWTYRIQEVSGSCNLPAAIFYL PKRHRKVCGNPKSREVQRAMKLLDARNKVFAKLHHNTQTFQA GPHAVKKLSSGNSKLSSSKFSNPISSSKRNVSLLISANSGL

DESCRIPTION OF THE EMBODIMENTS OF THE INVENTION

The present invention provides an efficient and rapid *in vitro* method for diagnosing a neurodegenerative disease by directly detecting an amount of QC in a biological sample obtained from a subject and comparing the detected amount of QC with an amount of QC characteristic of a normal control . An elevated amount of QC in the biological sample of the subject is a positive indication of AD or MCI or NDS. Thus, as described herein, it is demonstrated that QC is consistently and significantly elevated in a biological sample of AD, NDS or MCI patients compared to normal controls. As such, the methods for diagnosing AD, MCI or NDS of the present invention by detecting or quantifying the amount of QC in a patient sample will greatly

improve current clinical diagnostic assessment for patients suffering from these neurodegenerative diseases.

Accordingly, there is provided a method for assessing whether a subject may be suffering from AD, MCI or NDS using QC as a biological marker.

Glutaminyl cyclase or glutaminyl-peptide cyclotransferase (QC, EC 2.3.2.5) catalyzes the intramolecular cyclization of N-terminal glutaminyl residues into pyroglutamic acid (5-oxo-proline, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamyl residues into pyroglutamic acid under liberation of water.

A QC was first isolated by Messer from the Latex of the tropical plant Carica papaya in 1963 (Messer, M. 1963 Nature 4874, 1299). 24 years later, a corresponding enzymatic activity was discovered in animal pituitary (Busby, W. H. J. et al. 1987 *J Biol Chem* 262, 8532-8536; Fischer, W. H. and Spiess, J. 1987 *Proc Natl Acad Sci* U S A 84, 3628-3632). For the mammalian QCs, the conversion of Gln into pGlu by QC could be shown for the precursors of TRH and GnRH (Busby, W. H. J. et al. 1987 *J Biol Chem* 262, 8532-8536; Fischer, W. H. and Spiess, J. 1987 *Proc Natl Acad Sci* U S A 84, 3628-3632). In addition, initial localization experiments of QC revealed a co-localization with its putative products of catalysis in the bovine tractus hypothalamo-hypophysalisfurther improving the suggested function in peptide hormone maturation (Bockers, T. M. et al. 1995 *J Neuroendocrinol* 7, 445-453). In contrast, the physiological function of the plant QC is less clear. In case of the enzyme from C. papaya, a role in the plant defence against pathogenic microorganisms was suggested (El Moussaoui, A. et al. 2001 *Cell Mol Life Sci* 58, 556-570). Putative QCs from other plants were identified by sequence comparisons recently (Dahl, S. W. et al. 2000 *Protein Expr Purif* 20, 27-36). The physiological function of these enzymes, however, is still ambiguous.

The QCs known from plants and animals show a strict specificity for L-Glutamine in the N-terminal position of the substrates and their kinetic behaviour was found to obey the Michaelis-Menten equation (Pohl, T. et al. 1991 *Proc Natl Acad Sci U S A* 88, 10059-10063; Consalvo, A. P. et al. 1988 *Anal Biochem* 175, 131-138; Gololobov, M. Y. et al. 1996 *Biol Chem* Hoppe Seyler 377, 395-398). A comparison of the primary structures of the QCs from C. papaya and that of the highly conserved QC from mammals, however, did not reveal any sequence

homology (Dahl, S. W. et al. (2000) *Protein Expr Purif* 20, 27-36). Whereas the plant QCs appear to belong to a new enzyme family (Dahl, S. W. et al. (2000) *Protein Expr Purif* 20, 27-36), the mammalian QCs were found to have a pronounced sequence homology to bacterial aminopeptidases (Bateman, R. C. et al. 2001 *Biochemistry* 40, 11246-11250), leading to the conclusion that the QCs from plants and animals have different evolutionary origins.

Gostranova et al. have found that glutaminyl cyclase activity is a characteristic feature of cerebrospinal fluid in multiple sclerosis patients and controls (Gostranova et al., Clin Chim Acta. 2008 *389* (1-2), pp. 152-159).

Different isoforms of QC, the glutaminyl-peptide cyclotransferase-like proteins (QPCTLs) have been observed (WO 2008/034891). These novel proteins have significant sequence similarity to glutaminyl cyclase, e.g. the QPCTL from human (further named as isoQC) (GenBank accession no. NM_017659).

Multiple isoforms of a protein, such as QC or human isoQC, can also be produced from a single gene by a variety of mechanisms, including alternative RNA splicing, post- translational proteolytic processing and cell type-specific glycosylation. Thus, the terms "glutaminyl cyclase", "QC" and "isoQC" as used herein refer to QC in its native form, as well as any of its isoforms.

Preferred for the use of the present invention are human QC or its isoforms, having an amino acid sequence selected from the group of SEQ ID NO's: 1, 2, 3, 4 and 5.

More preferred for use in the methods of the present invention is the human QPCTL having an amino acid sequence of SEQ ID NO. 2, or even preferred of SEQ ID NO: 3.

Even preferred for use in the methods of the present invention are spliceforms of human QPCTL having an amino acid sequence of SEQ ID NO. 4 or of SEQ ID NO: 5.

Most preferred for use in the methods of the present invention is human QC having the amino acid sequence of SEQ ID NO: 1.

Thus, according to a first aspect of the present invention, there is provided a method for diagnosing probable Alzheimer's Disease (AD), Neurodegeneration in Down's Syndrome (NDS) or Mild Cognitive Impairment (MCI) in a subject, the method comprising:

(a) detecting the amount of glutaminyl cyclase (QC), or an isoform thereof, in a biological sample obtained from said subject; and

(b) comparing the detected amount of QC in the biological sample with an amount of QC characteristic of a normal control;

whereby an elevated amount of QC in said biological sample relative to the normal control is a positive indicator of AD, NDS or MCI.

It has been demonstrated by inventors of the present invention that an elevated amount of QC in a biological sample may correlate with an elevated amount of N-terminally truncated and pyroglutamated amyloid beta peptides, such as for example Aβ N3pE-42 and/or Aβ N3pE-40 and/or Aβ N3pE-38.

Thus, according to a further aspect of the present invention, there is provided a method for diagnosing probable Alzheimer's Disease (AD), Neurodegeneration in Down's Syndrome (NDS) or Mild Cognitive Impairment (MCI) in a subject, the method comprising:

(a) detecting the amount of glutaminyl cyclase (QC), or an isoform thereof, in a biological sample obtained from said subject; and

(b) further detecting the amount of Aβ N3pE-X,

(c) comparing the detected amount of QC and Aβ N3pE-X in the biological sample with an amount of QC and Aβ N3pE-X characteristic of a normal control;

whereby an elevated amount of QC and Aβ N3pE-X in said biological sample relative to the normal control is a positive indicator of AD, NDS or MCI, and

wherein X is an integer selected from 38, 40 and 42.

In a preferred embodiment, X is 42.

In a further preferred embodiment, X is 40.

In a yet preferred embodiment, X is 38.

Further preferred are methods, wherein not only a single form of the N-terminally truncated and pyroglutamated amyloid beta peptides but a combination of Aβ N3pE-42 and/or Aβ N3pE-40 and/or Aβ N3pE-38 is detected together with QC.

Further preferred are methods, wherein not only a single form of the N-terminally truncated and pyroglutamated amyloid beta peptides but a combination of Aβ N3pE-42 and/or Aβ N3pE-40 and/or Aβ N3pE-38 and/or peptides occurring in familial Alzheimer's dementias, such as pGluABri or pGluADan, is detected together with QC.

"pGlu-Aβ" or "Aβ N3pE" refers to N-terminally truncated forms of Aβ, that start at the glutamic acid residue at position 3 in the amino acid sequence of Aβ, and wherein said glutamic acid residue is cyclized to form a pyroglutamic acid residue. In particular, by pGlu-Aβ as used herein are meant those fragments which are involved in or associated with the amyloid pathologies including, but not limited to, pGlu-Aβ 3-38, pGlu-Aβ 3-40, p-Glu-Aβ 3-42.

It has further been demonstrated by the inventors of the present invention that an elevated amount of QC in a biological sample may correlate with an elevated amount of a chemokine, such as for example CCL2, CCL7, CCL8, CCL9/10, CCL13, CCL15, CCL16, CCL25 and Fractalkine.

Thus, according to a further aspect of the present invention, there is provided a method for diagnosing Alzheimer's Disease (AD), Neurodegeneration in Down's Syndrome (NDS) or Mild Cognitive Impairment (MCI) in a subject, the method comprising:

(a) detecting the amount of glutaminyl cyclase (QC), or an isoform thereof, in a biological sample obtained from said subject; and

(b) further detecting the amount of a chemokine,

(c) comparing the detected amount of QC and the chemokine in the biological sample with an amount of QC and the chemokine characteristic of a normal control;

whereby an elevated amount of QC and chemokine in said biological sample relative to the normal control is a positive indicator of AD, NDS or MCI.

In a preferred embodiment, said chemokine is of mammalian origin. More preferably, said chemokine is a human chemokine. Most preferably, said chemokine is human CCL2.

In a further preferred embodiment, any of the aforementioned methods for diagnosing Alzheimer's Disease (AD), Neurodegeneration in Down's Syndrome (NDS) or Mild Cognitive Impairment (MCI) may also be performed in vitro in a biological sample of a subject.

The term "subject" refers to a mammal which is afflicted with, or suspected to be afflicted with a neurogenerative disease such as AD, MCI or NDS. Preferably, "subject" refers to a human.

The term "biological sample" refers to any source of biological material, including, but are not limited to, peripheral blood, plasma, lymphocytes, cerebrospinal fluid, urine, saliva, epithelia, fibroblasts, or any other sample comprising QC protein.

In a preferred embodiment, the amount of QC is detected in a body fluid sample obtained from a mammal, most preferably a human. The term "body fluid" refers to all fluids that are present in the human body including but not limited to blood, lymph, urine and cerebrospinal fluid (CSF) comprising QC. The blood sample may include a plasma sample or a serum sample, or fractions derived from these samples. The sample can be treated prior to use, such as preparing plasma from blood, diluting viscous fluids, and the like. Preferably, the plasma sample is treated with an anti -coagulant , such as EDTA.

According to a preferred embodiment of the present invention, the amount of QC is detected in a blood sample taken from the subject, more preferably a plasma sample. Thus, the present invention preferably relates to a method as described above, comprising the steps of: obtaining a plasma sample from said subject; detecting the amount of QC in the plasma sample; comparing the detected amount of QC in the plasma sample with the amount of QC in a plasma sample from a normal control, whereby an elevated amount of QC relative to the normal control is a positive indication of AD, NDS or MCI. Elevated amounts of QC have been shown to correlate with and are useful in aiding the diagnosis of AD, NDS and MCI.

An "elevated amount" of QC (or an isoform thereof) means that the amount of QC detected in the samples of the subjects is greater than the mean amount of QC characteristic of a normal control person beyond the range of experimental error, as known in the art. Preferably, the amount of QC detected in the samples of the subjects is 10 % greater than said mean amount of

QC characteristic of a normal control person. More preferably, the amount of QC (or an isoform thereof) detected in the samples of the subjects is 25 % greater, or, even more preferred 50 % or 75 % greater than said mean amount of QC characteristic of a normal control person. Most preferably, the amount of QC (or an isoform thereof) detected in the samples of the subjects is several times greater than said mean amount of QC characteristic of a normal control person, e.g. 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times greater.

A "normal control" is a biological sample of the same type obtained from the subject, for example that is obtained from at least one normal age-matched control person or from the patient at another time. In an embodiment, the normal control is taken from the patient at an earlier time. A normal control sample from a normal age-matched population should be isolated from an adequate population sample of healthy age matched controls with no history of AD, MCI or NDS in their family. By way of example, a plasma QC level higher than the control levels of QC, as determined by an adequate control population sample size, is indicative of AD, NDS or MCI. One of skill in the art will appreciate that the sample from the subject to be diagnosed is assessed against a normal age-matched control and that a significant elevation or reduction in the amount of QC in the subject's protein sample is determined based on comparison to the controls used in the given assay.

According to a further embodiment of the present invention, the amount of QC, or an isoform thereof, is detected either on the basis of the protein level or the mRNA level of said QC or isoform thereof.

The amount of QC detected or quantified in a subject's biological sample can be accomplished by any means known in the art. Such means may include, but are not limited to, for example by immunoturbidimetric assay, immunofluorescence, immunodiffusion, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), Western Blot, protein activity assay, or, for the determination of the QC mRNA level, Northern Blot or polymerase chain reaction (PCR) analysis, for example real-time PCR. Also useful are high performance liquid chromatography (HPLC) , mass spectrometry (MS) and gas chromatography (GC) , as well as their various configurations, including gas chromatograph-mass spectrometry (GC-MS) , liquid chromatography-mass spectrometry (LC-MS) and liquid-chromatography-tandem mass spectrometry (LC-MS/MS) systems, to name a few.

While detection of QC can be accomplished by methods known in the art for detecting peptides, the use of immmunological detection techniques using antibodies, antibody fragments, recombinant antibodies, and the like, is preferred. Therefore, such detection of QC includes, but is not limited to, the use of antibodies, which specifically bind to QC, or its isoforms, to form an immune complex, as well as reagents for detecting the formation of the immune complex. Particularly suitable detection techniques employing one or more antibodies include immunoturbidimetric assay, immunofluorescence, immunodiffusion, ELISA, RIA and the like.

Such antibodies may be polyclonal or monoclonal. Methods to produce polyclonal or monoclonal antibodies are well known in the art. For a review, see Harlow and Lane (Harlow, E. and Lane, D., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988) and Yelton et al . (Yelton D. E. and Scharff M. D. Monoclonal Antibodies: a powerful new tool in biology and medicine. Ann. Rev. Biochem. 50:657-680, 1981), both of which are herein incorporated by reference. For monoclonal antibodies, see Kohler and Milstein (Kohler G. and Milstein C, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature 256:495-497, 1975), herein incorporated by reference. The antibodies of the invention are of any isotype, e.g., IgG or IgA, and polyclonal antibodies are of a single isotype or a mixture of isotypes.

According to a preferred embodiment of the invention, the anti-QC antibody is a monoclonal antibody. Although anti-QC antibodies are widely commercially available, antibodies for use in the various immunoassays described herein, can be produced according to standard methods.

Further, the monoclonal anti-QC antibody is capable of recognizing QC in its native form, as well as any of its isoforms. Thus, any monoclonal antibody that specifically recognizes QC, including its isoforms, can be used in said method for the quantification of QC.

Preferred are monoclonal antibodies, that specifically recognize QC but show low, or more preferably, no crossreactivity with isoforms of QC. Alternatively preferred are monoclonal antibodies that specifically recognize a particular isoform of QC but show low, or more preferably, no crossreactivity with QC.

Suitable anti-QC antibodies are, for example, those which are commercially available from Abnova (Taipei City, Taiwan), e.g. a mouse polyclonal antibody (Cat. # H00025797-B01P) and a rabbit polyclonal antibody (Cat. # H00025797-D01P).

A suitable anti-QPCTL antibody is, for example, the commercially available mouse polyclonal antibody from Abnova (Taipei City, Taiwan, Cat. # H00054814-B01P).

Also fragments derived from these monoclonal antibodies such as Fab, $F(ab)_2$, ssFv (single chain variable fragment) and other antibody-like constructs that retain the variable region of the antibody, providing they have retained the original binding properties, can be used in a method of the present invention. Such fragments are commonly generated by, for instance, enzymatic digestion of the antibodies with papain, pepsin, or other proteases. It is well known to the person skilled in the art that monoclonal antibodies, or fragments thereof, can be modified for various uses. Thus, antibodies of the invention, may be recombinant, e.g., chimeric (e.g., constituted by a variable region of murine origin associated with a human constant region), humanized (a human immunoglobulin constant backbone together with hypervariable region of animal, e.g., murine, origin), and/or single chain.

An antibody specific for QC, or its isoforms, used in a method of the present invention may be labelled by an appropriate label and identified in the biological sample based upon the presence of the label. The label allows for the detection of the antibody when it is bound to QC. Examples of labels include, but are not limited to, the following: radioisotopes (e.g., ^{3}H, ^{14}C, ^{35}S, ^{125}I, ^{131}I), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), luminescent labels, enzymatic labels (e.g., horseradish peroxidase, beta-galactosidase, luciferase, alkaline phosphatase), chemiluminescent , and biotinyl groups .
Methods for conjugating or labelling the antibodies discussed above may be readily accomplished by one of ordinary skill in the art (see for example Inman, "Methods In Enzymology" , Vol. 34, Affinity Techniques, Enzyme Purification: Part B, Jakoby and Wichek (eds.), Academic Press, New York, p. 30, 1974; and Wilchek and Bayer, "The Avidin-Biotin Complex in Bioanalytical Applications," Anal. Biochem. 171:1-32, 1988).

For diagnostic applications, the anti-QC antibody is either in a free state or immobilized on a solid support, such as a tube, a bead, or any other conventional support used in the field.

Immobilization is achieved using direct or indirect means. "Direct means" include passive adsorption (non-covalent binding) or covalent binding between the support and the reagent. By "indirect means" is meant that an anti-reagent compound that interacts with a reagent is first attached to the solid support. Indirect means may also employ a ligand-receptor system, for example, where a molecule such as a vitamin is grafted onto the reagent and the corresponding receptor immobilized on the solid phase. This is illustrated by the biotin-streptavidin system.

Those skilled in the art will readily understand that an immune complex is formed between QC in the biological sample and the antibody, and that any unbound material is removed prior to detecting the complex. It is understood that an antibody of the invention is used for quantifying an amount of QC in the biological sample, such as, for example, blood, plasma, lymphocytes, cerebrospinal fluid, urine, saliva, epithelia and fibroblasts.

As is known in the art, the determination of such antibody binding can be performed using a great variety of immunoassay formats including, but not limited to immunoturbidimetric assay (agglutination) , enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay (RIA) (see, for example, "Principles and Practice of Immunoassay" (1991) Christopher P. Price and David J. Neoman (eds) , Stockton Press, New York, N. Y. and Ausubel et al . (eds) (1987) in "Current Protocols in Molecular Biology" John Wiley and Sons, New York, N. Y., both of which are incorporated herein by reference) . Detection may be by colormetic or radioactive methods or any other conventional methods known to one skill in the art. Other standard techniques known in the art are described in "Methods in Immunodiagnosis" , 2nd Edition, Rose and Bigazzi, eds., John Wiley and Sons, New York 1980 and Campbell et al . ; "Methods of Immunology", W. A. Benjamin, Inc., 1964; U.S. Patent Nos . 4,366,241; 4,376,110; 4,517,288; and 4,837,168, the disclosures of which are incorporated herein by reference. For a review of the general immunoassays, see also "Methods In Cell Biology", Vol. 37, Asai, ed. Academic Press, Inc. New York (1993) ; "Basic And Clinical Immunology" 7th Edition, Stites & Terr, eds. (1991) .

Such assays for detecting QC may be a direct, indirect, competitive, or noncompetitive immunoassay as described in the art (see, for example, "Principles and Practice of Immunoassay" (1991) Christopher P. Price and David J. Neoman (eds), Stockton Press, New York, N.Y.; Ausubel et al . (eds) (1987) in "Current Protocols in Molecular Biology" John Wiley

and Sons, New York, N. Y.; and Oellirich, M. 1984. J. Clin. Chem. Clin. Biochem. 22: 895-904, incorporated herein by reference).

Noncompetitive immunoassays are assays in which the amount of QC is directly detected. In the "sandwich" assay, for example, the anti-QC antibodies can be bound directly to a solid substrate where they are immobilized. These immobilized antibodies then capture the QC present in the biological sample. The QC thus immobilized is then bound by a labeling agent, such as a second human QC antibody bearing a label.

In a competitive immunoassay, the amount of antigen present in the biological sample is determined indirectly following addition of a known amount of labeled antigen to the sample and detecting the amount of labeled antigen bound with antibodies. For example, a known amount of, in this case, labeled QC is added to the biological sample and the sample is then contacted with anti-QC antibodies. The amount of labeled QC bound to the anti-QC antibody is inversely proportional to the concentration of QC in the biological sample. This is because the greater the amount of labeled QC detected, the less the amount of QC was available in the biological sample to compete with the labeled QC.

Diagnostic kits for carrying out the assays for diagnosing AD, MCI or NDS in a subject are also provided. Thus, the present invention can be practiced using a diagnostic kit that includes at least one antibody specific for QC, and its isoforms, as described herein as well as any reagents necessary for the detection of antibody-QC binding immune complexes. Generally, the kit may include a single antibody that specifically recognizes QC, and its isoforms. On the other hand, the kit may include a primary antibody that specifically recognizes QC, and its isoforms, as well as a secondary antibody that is conjugated with a signal-producing label and is capable of binding to the primary antibody, or at a site different from the site where the primary antibody binds. The signal-producing label linked to the secondary antibody may be, but is not limited to, an enzyme, such as horseradish peroxidase or alkaline phosphatase. The kits may further comprise other reagents for carrying out the assay such as buffers, a solid support, solutions and the like. The kit may also contain instructions for carrying out the method of the invention using one or more antibodies in diagnostic assays.

Comprises/comprising and grammatical variations thereof when used in this specification are to be taken to specify the presence of stated features, integers, steps or components or groups thereof, but do not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.

5

EXAMPLES OF THE INVENTION

Example 1: Formation of Aβ N3pE-42 and QC expression in vivo

A widespread QC distribution has been detected in mammalian brain with considerable expression in hippocampus and cortex. In order to assess whether QC expression in AD can be correlated with generation of Aβ N3pE-42, QC mRNA and protein concentrations were analyzed in human neocortical brain samples *post mortem* (Figure 1a, b). Intriguingly, the inventors found an upregulation of QC mRNA and protein in AD brain samples, compared to normal aging. Moreover, significant concentrations of Aβ N3pE-42 were detected in samples from AD patients in contrast to non-demented individuals supporting a role of QC in generation of Aβ N3pE-42 (Figure 1c). On the other hand, ELISA analysis revealed high Aβ x-42 concentrations in normally aged control subjects and a much smaller increase at early AD stages (Figure 1c). This observation was corroborated by immunohistochemistry applying antibodies detecting total Aβ (4G8) or specifically Aβ N3pE-42 (Figure 1d). Conspicuous immunoreactivity for Aβ was detected in brain sections from all groups. In contrast, Aβ N3pE-42 staining was absent in normal aging but specific for AD brain tissue, where Aβ N3pE-42-immunoreactive plaque load was almost as high as the total of Aβ plaque density.

Material and methods

Human brain tissue

The definite diagnosis of AD for all cases used in this study was based on the presence of neurofibrillary tangles and neuritic plaques in the hippocampal formation and neocortical areas and met the criteria of the National Institute of Neurologic and Communicative Disorders and Stroke (NINDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA). Cortical tissue (Brodmann area 22) from the same cases was used for the quantification of QC mRNA concentrations, QC protein and Aβ N3pE-42. In total, 10 control cases and 10 AD cases each of Braak staging I-II and V-VI were analyzed. The groups were matched for gender and age (control: mean 72 years ± 6.6 years; AD I-II: mean 73 years ± 3.1 years; AD V-VI: mean 77 years ± 6.6 years). The mean post morten interval (PMI) was similar among the groups and ranged from 26 to 96 hours. The duration of PMI was neither related to the detection of QC by Western blot analysis nor to quantification of Aβ by ELISA. For QC mRNA detection by qRT-PCR, only tissue samples with a PMI below 48 hours were included.

QC mRNA quantification and QC Western blot analysis

Tissue samples were homogenized by means of the homogenizer Precellys with 1.4 mm ceramic beads (5000 rpm, 30 sec, peqlab). RNA was isolated using the NucleoSpin RNA II kit (Macherey Nagel) according to the manufacturer's instructions. Constant 100 ng of RNA were reverse transcribed to cDNA using random primers (Roche) and Superscript II (Invitrogen). Quantitative real-time PCR was performed in a Rotorgene3000 (Corbett Research) using the QuantiTect Primer Assay for QPCT (QT00013881, Qiagen) as well as the QuantiTect SYBR Green RT-PCR kit (Qiagen). Absolute amounts of QC were determined using six dilutions of the external QC standard DNA (full length QC cloned in the pcDNA3 vector) in duplicate. For verification of the PCR, product melting curves were generated and single amplicons were confirmed by agarose gel electrophoresis. Absolute amounts were determined with the Rotorgene software version 4.6 in quantitation mode. Normalization was done against the two most stably expressed housekeeping genes HPRT and GAPDH (geNorm). For Western-Blot analysis, the brain samples (50 mg) were homogenized in buffer (1 ml) containing 10 mM Tris pH 7.5, 100 mM NaCl, 5 mM EDTA and 0.5% Triton X-100 and 10% glycerol. The tissue was homogenized by several strokes in Downs-homogenizer and subjected to 3x 10s of ultrasonic shock. The resulting homogenate was cleared by centrifugation at 20000x*g* for 25 min. A total of 12 µg protein of each sample was separated in Tris-Glycine SDS-PAGE. QC was detected using purified rabbit polyclonal antibodies raised against recombinant human QC. For visualization, blot membranes were incubated with secondary antibody conjugated with horseradish peroxidase (Cell Signaling) in TBS-T containing 5 % (w/v) dry milk and subsequently developed using the SuperSignal West Pico System (Pierce) according to the manufacturer's protocol.

Example 2: Determination of gene expression rate of QC and CCL2 in stimulated THP-1 cells

Human monocytic leukaemia cell line THP-1 cells were cultivated in suspension ($5x10^5$ cells per ml medium) in RPMI-1640 (Rosewell Park Memorial Institute Medium 1640 (Invitrogen)) containing 10% FCS (=FBS, Fetal Bovine Serum (Invitrogen)) and 60 µg/ml gentamycin (Invitrogen) at 37 °C in 5% CO_2 and 95% air humidified atmosphere.

To investigate stimulation effects of QC and CCL2 $2x10^6$ cells were seeded in 24 well plates (Greiner) into 1 ml culture medium without FCS containing different concentrations of lipopolysaccharides (LPS; Sigma). After 24 h incubation the medium was removed from the cells by centrifugation (5 min 300 x g).

RNA isolation was carried out with the Nucleo-Spin® RNA II Kit (Macherey & Nagel) followed by the determination of the RNA concentration. Using the SuperScript™ II Reverse Transcriptase Kit from Invitrogen 1 µg RNA was transcribed into cDNA.

The gene expression rate of QC and CCL2 was determined via quantitative PCR with the real time cycler Rotor-Gene™ 3000. Using the comparative method of the operating software the change of the gene expression rate of the stimulated probes compared to the unstimulated control could be shown. The normalisation was performed against the reference gene YWHAZ (Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein). The results are shown in Figure 2.

Example 3: Determination of the specific QC activity in conditioned medium of THP-1 cells

$5x10^6$ THP-1 cells were seeded into 5 ml RPMI-1640 (Invitrogen) without phenol red and without FCS into 25 cm^2 suspension flasks (Greiner) and stimulated with different concentrations of LPS (Sigma). After 24 h incubation at 37 °C and 5 % CO_2 cells were separated from the medium, which was reduced by centrifugation (4000 x g) using U-Tube™ Concentrators 6-10 (Merck, Novagen) with a MWCO (Moleculare Weight Cut Off) 10 kDa to a final volume of 250 µl. The analysis of the protein concentration via Bradford method followed. The determination of the specific QC activity was realised by using a in-house established HPLC method. The results are shown in Figure 3.

Example 4: Determination of QC activity

Fluorometric assays

All measurements were performed with a BioAssay Reader HTS-7000Plus for microplates (Perkin Elmer) at 30 °C. QC activity was evaluated fluorometrically using H-Gln-bNA. The samples consisted of 0.2 mM fluorogenic substrate, 0.25 U pyroglutamyl aminopeptidase (Unizyme, Hørsholm, Denmark) in 0.2 M Tris/HCl, pH 8.0 containing 20 mM EDTA and an appropriately diluted aliquot of QC in a final volume of 250 µl. Excitation/emission wavelengths were 320/410 nm. The assay reactions were initiated by addition of glutaminyl cyclase. QC activity was determined from a standard curve of b-naphthylamine under assay conditions. One unit is defined as the amount of QC catalyzing the formation of 1 µmol pGlu-bNA from H-Gln-bNA per minute under the described conditions.

In a second fluorometric assay, QC was activity determined using H-Gln-AMC as substrate. Reactions were carried out at 30 °C utilizing the NOVOStar reader for microplates (BMG labtechnologies). The samples consisted of varying concentrations of the fluorogenic substrate, 0.1 U pyroglutamyl aminopeptidase (Qiagen) in 0.05 M Tris/HCl, pH 8.0 containing 5 mM EDTA and an appropriately diluted aliquot of QC in a final volume of 250 µl. Excitation/emission wavelengths were 380/460 nm. The assay reactions were initiated by addition of glutaminyl cyclase. QC activity was determined from a standard curve of 7-amino-4-methylcoumarin under assay conditions. The kinetic data were evaluated using GraFit software.

Spectrophotometric assay of QC

In this assay, QC activity was analyzed spectrophotometrically using a continuous method, that was derived by adapting a previous discontinuous assay (Bateman, R. C. J. 1989 J Neurosci Methods 30, 23-28) utilizing glutamate dehydrogenase as auxiliary enzyme. Samples consisted of the respective QC substrate, 0.3 mM NADH, 14 mM a-Ketoglutaric acid and 30 U/ml glutamate dehydrogenase in a final volume of 250 µl. Reactions were started by addition of QC and persued by monitoring of the decrease in absorbance at 340 nm for 8-15 min.

The initial velocities were evaluated and the enzymatic activity was determined from a standard curve of ammonia under assay conditions. All samples were measured at 30 °C, using either the SPECTRAFluor Plus or the Sunrise (both from TECAN) reader for microplates. Kinetic data was evaluated using GraFit software.

CLAIMS

1. A method for diagnosing Alzheimer's Disease (AD), Neurodegeneration in Down's Syndrome (NDS) or Mild Cognitive Impairment (MCI) in a subject, the method comprising:

(a) detecting the amount of glutaminyl cyclase (QC), or an isoform thereof, in a biological sample obtained from said subject; and

(b) comparing the detected amount of QC in the biological sample with an amount of QC characteristic of a normal control;

whereby an elevated amount of QC in said biological sample relative to the normal control is a positive indicator of AD, NDS or MCI .

2. A method for diagnosing Alzheimer's Disease (AD), Neurodegeneration in Down's Syndrome (NDS) or Mild Cognitive Impairment (MCI) in a subject, the method comprising:

(a) detecting the amount of glutaminyl cyclase (QC), or an isoform thereof, in a biological sample obtained from said subject; and

(b) further detecting the amount of Aβ N3pE-X,

(c) comparing the detected amount of QC and Aβ N3pE-X in the biological sample with an amount of QC and Aβ N3pE-X characteristic of a normal control;

whereby an elevated amount of QC and Aβ N3pE-X in said biological sample relative to the normal control is a positive indicator of AD, NDS or MCI, and

wherein X is an integer selected from 38, 40 and 42.

3. A method for diagnosing Alzheimer's Disease (AD), Neurodegeneration in Down's Syndrome (NDS) or Mild Cognitive Impairment (MCI) in a subject, the method comprising:

(a) detecting the amount of glutaminyl cyclase (QC), or an isoform thereof, in a biological sample obtained from said subject; and

(b) further detecting the amount of a chemokine,

(c) comparing the detected amount of QC and the chemokine in the biological sample with an amount of QC and the chemokine characteristic of a normal control;

whereby an elevated amount of QC and chemokine in said biological sample relative to the normal control is a positive indicator of AD, NDS or MCI.

4. The method according to any one the preceding claims, wherein said QC is human QC or an isoform thereof, having an amino acid sequence selected from the group consisting of SEQ ID NO's: 1, 2, 3, 4 and 5.

5. The method according to any one of the preceding claims, wherein said QC is human QC of SEQ ID NO: 1.

6. The method according to any of the preceding claims, wherein said biological sample is serum, plasma, urine or cerebrospinal fluid.

7. The method according to any of the preceding claims, wherein said biological sample is plasma.

8. The method according to any of the preceding claims, wherein the amount of QC is detected by immunoturbidimetric assay, immunofluorescence, immunodiffusion, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), Western blot, protein activity assay, Northern Blot, PCR, high performance liquid chromatography (HPLC) , mass spectrometry (MS) , gas chromatography (GC), GC-MS, LC-MS, or LC-MS/MS.

9. The method according to any one of the preceding claims, wherein the amount of QC, or an isoform thereof, is detected on the basis of the protein level of said QC or isoform thereof.

10. The method according to any of the preceding claims, wherein the amount of QC is detected using an antibody that specifically binds to QC, or an isoform thereof.

11. The method according to any of the preceding claims, wherein the amount of QC is detected by measuring the enzymatic activity of QC, or an isoform thereof.

12. The method according to any one of claims 1 to 8, wherein the amount of QC, or an isoform thereof, is detected on the basis of the mRNA level of said QC or isoform thereof.

13. The method according to any one of claims 2, and 4 to 12, wherein X is 42.

14. The method according to any one of claims 2, and 4 to 12, wherein X is 40.

15. The method according to any one of claims 2, and 4 to 12, wherein X is 38.

16. The method according to any one of claims 2, and 4 to 12, wherein not only a single form of the N-terminally truncated and pyroglutamated amyloid beta peptides but a combination of Aβ N3pE-42 and/or Aβ N3pE-40 and/or Aβ N3pE-38, and pGluABri and/or pGluADan is detected together with QC.

17. The method according to any one of claims 3 to 12, wherein said chemokine is selected from CCL2, CCL7, CCL8, CCL9/10, CCL13, CCL15, CCL16, CCL25 and Fractalkine.

18. The method according to any one of claims 3 to 12, wherein said chemokine is CCL2.

19. A method of diagnosing a neurodegenerative disease in a subject, the method comprising:

(a) obtaining a biological sample from said subject ;

(b) contacting said biological sample with an antibody that binds to glutaminyl cyclase (QC), or its isoforms ;

(c) allowing the antibody and QC to form an immune complex; and

(d) detecting the amount of immune complex formed as an indication of the amount of QC in said biological sample; and

(e) comparing the detected amount to a sample from normal control subject;

whereby a detected amount that is elevated or reduced relative to the normal control is a positive indicator of a neurodegenerative disease.

20. The method according to claim 19, wherein the detected amount that is elevated relative to the normal control is a positive indicator for AD.

21. The method according to claim 19, wherein the detected amount that is elevated relative to the normal control is a positive indicator of MCI.

22. The method according to claim 19, wherein the detected amount that is elevated relative to the normal control is a positive indicator of NDS.

23. An *in vitro* method for diagnosing Alzheimer's Disease (AD), Neurodegeneration in Down's Syndrome (NDS) or Mild Cognitive Impairment (MCI) in a biological sample from a subject, the method comprising:

(a) detecting the amount of glutaminyl cyclase (QC), or an isoform thereof, in said biological sample; and

(b) comparing the detected amount of QC in said biological sample with an amount of QC characteristic of a normal control;

whereby an elevated amount of QC in said biological sample relative to the normal control is a positive indicator of AD, NDS or MCI .

24. An *in vitro* method for diagnosing Alzheimer's Disease (AD), Neurodegeneration in Down's Syndrome (NDS) or Mild Cognitive Impairment (MCI) in a biological sample from a subject, the method comprising:

(a) detecting the amount of glutaminyl cyclase (QC), or an isoform thereof, in said biological sample; and

(b) further detecting the amount of Aβ N3pE-X,

(c) comparing the detected amount of QC and Aβ N3pE-X in the biological sample with an amount of QC and Aβ N3pE-X characteristic of a normal control;

whereby an elevated amount of QC and Aβ N3pE-X in said biological sample relative to the normal control is a positive indicator of AD, NDS or MCI, and

wherein X is an integer selected from 38, 40 and 42.

25. An *in vitro* method for diagnosing Alzheimer's Disease (AD), Neurodegeneration in Down's Syndrome (NDS) or Mild Cognitive Impairment (MCI) in a biological sample of a subject, the method comprising:

(a) detecting the amount of glutaminyl cyclase (QC), or an isoform thereof, in said biological sample; and

(b) further detecting the amount of a chemokine,

(c) comparing the detected amount of QC and the chemokine in the biological sample with an amount of QC and the chemokine characteristic of a normal control;

whereby an elevated amount of QC and chemokine in said biological sample relative to the normal control is a positive indicator of AD, NDS or MCI.

26. The *in vitro* method according to any one of claims 23, 24 or 25, wherein said QC is human QC or an isoform thereof, having an amino acid sequence selected from the group consisting of SEQ ID NO's: 1, 2, 3, 4 and 5.

27. The *in vitro* method according to any one of claims 23 to 26, wherein said QC is human QC of SEQ ID NO: 1.

28. The *in vitro* method according to any of the claims 23 to 27, wherein said biological sample is serum, plasma, urine or cerebrospinal fluid.

29. The *in vitro* method according to any of the claims 23 to 28, wherein said biological sample is plasma.

30. The *in vitro* method according to any of the claims 23 to 29, wherein the amount of QC is detected by immunoturbidimetric assay, immunofluorescence, immunodiffusion, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), Western blot, protein activity assay, Northern Blot, PCR, high performance liquid chromatography (HPLC) , mass spectrometry (MS) , gas chromatography (GC), GC-MS, LC-MS, or LC-MS/MS.

31. The *in vitro* method according to any one of the claims 23 to 30, wherein the amount of QC, or an isoform thereof, is detected on the basis of the protein level of said QC or isoform thereof.

32. The *in vitro* method according to any of the claims 23 to 31, wherein the amount of QC is detected using an antibody that specifically binds to QC, or an isoform thereof.

33. The *in vitro* method according to any of the claims 23 to 30, wherein the amount of QC is detected by measuring the enzymatic activity of QC, or an isoform thereof.

34. The *in vitro* method according to any one of claims 23 to 30, wherein the amount of QC, or an isoform thereof, is detected on the basis of the mRNA level of said QC or isoform thereof.

35. The *in vitro* method according to any one of claims 24, and 26 to 34, wherein X is 42.

36. The *in vitro* method according to any one of claims 24, and 26 to 34, wherein X is 40.

37. The *in vitro* method according to any one of claims 24, and 26 to 34, wherein X is 38.

38. The *in vitro* method according to any one of claims 24, and 26 to 34, wherein not only a single form of the N-terminally truncated and pyroglutamated amyloid beta peptides but a combination of Aβ N3pE-42 and/or Aβ N3pE-40 and/or Aβ N3pE-38 and/or pGluABri and/or pGluADan is detected together with QC.

39. The *in vitro* method according to any one of claims 25 to 34, wherein the chemokine is selected from CCL2, CCL7, CCL8, CCL9/10, CCL13, CCL15, CCL16, CCL25 and Fractalkine

40. The *in vitro* method according to any one of claims 25 to 34, wherein the chemokine is CCL2.

41. An *in vitro* method of diagnosing a neurodegenerative disease in a biological sample from a subject, the method comprising:

(a) contacting said biological sample with an antibody that binds to glutaminyl cyclase (QC), or an isoform thereof;

(b) allowing the antibody and QC to form an immune complex; and

(c) detecting the amount of immune complex formed as an indication of the amount of QC in said biological sample; and

(d) comparing the detected amount to a sample from normal control subject;

whereby a detected amount that is elevated or reduced relative to the normal control is a positive indicator of a neurodegenerative disease.

42. The *in vitro* method according to claim 41, wherein the detected amount that is elevated relative to the normal control is a positive indicator for AD.

43. The *in vitro* method according to claim 41, wherein the detected amount that is elevated relative to the normal control is a positive indicator of MCI.

44. The in vitro method according to claim 41, wherein the detected amount that is elevated relative to the normal control is a positive indicator of NDS.

45. A kit for diagnosing a neurodegenerative disease when used in the method according to claim 1 comprising:

(a) an antibody that binds to QC; and

(b) an established standard of an amount of QC characteristic of a normal control

46. A method of using an antibody that binds to glutaminyl cyclase (QC) or an isoform thereof as a biological marker, for diagnosing a neurodegenerative disease, said method of using comprising contacting a biological sample obtained from a subject with said antibody to determine the amount of QC in the sample, according to claim 1.

47. Use of an antibody that binds to glutaminyl cyclase (QC) or an isoform thereof as a biological marker, for diagnosing a neurodegenerative disease in a subject, when used in the method according to claim 1.

PROBIODRUG AG

WATERMARK PATENT AND TRADE MARKS ATTORNEYS

P34093AU00

FIGURES

Figure 1



Figure 2


7
6
5
4
3
2
1
0
QC
CCL2
fold change of mRNA expression
control
LPS 100 ng/ml
LPS 1 µg/ml
LPS 10 µg/ml

Figure 3


specific QC activity [nmol/h/mg]
10
8
6
4
2
0
control
LPS 100 ng/ml
LPS 1 µg/ml
LPS 10 µg/ml

SEQUENCE LISTING

<110> Probiodrug AG

<120> Glutaminyl cyclase as a diagnostic/prognostic indicator for neurodegenerative diseases

<130> PBD 00072/WO

<150> US 61/085,154
<151> 2008-07-31

<160> 22

<170> PatentIn version 3.5

<210> 1
<211> 361
<212> PRT
<213> Homo sapiens

<400> 1

Met Ala Gly Gly Arg His Arg Arg Val Val Gly Thr Leu His Leu Leu
1 5 10 15

Leu Leu Val Ala Ala Leu Pro Trp Ala Ser Arg Gly Val Ser Pro Ser
20 25 30

Ala Ser Ala Trp Pro Glu Glu Lys Asn Tyr His Gln Pro Ala Ile Leu
35 40 45

Asn Ser Ser Ala Leu Arg Gln Ile Ala Glu Gly Thr Ser Ile Ser Glu
50 55 60

Met Trp Gln Asn Asp Leu Gln Pro Leu Leu Ile Glu Arg Tyr Pro Gly
65 70 75 80

Ser Pro Gly Ser Tyr Ala Ala Arg Gln His Ile Met Gln Arg Ile Gln
85 90 95

Arg Leu Gln Ala Asp Trp Val Leu Glu Ile Asp Thr Phe Leu Ser Gln
100 105 110

Thr Pro Tyr Gly Tyr Arg Ser Phe Ser Asn Ile Ile Ser Thr Leu Asn
115 120 125

Pro Thr Ala Lys Arg His Leu Val Leu Ala Cys His Tyr Asp Ser Lys
130 135 140

Tyr Phe Ser His Trp Asn Asn Arg Val Phe Val Gly Ala Thr Asp Ser
145 150 155 160

Ala Val Pro Cys Ala Met Met Leu Glu Leu Ala Arg Ala Leu Asp Lys
165 170 175

Lys Leu Leu Ser Leu Lys Thr Val Ser Asp Ser Lys Pro Asp Leu Ser
180 185 190

```
Leu Gln Leu Ile Phe Phe Asp Gly Glu Glu Ala Phe Leu His Trp Ser
        195                 200                 205

Pro Gln Asp Ser Leu Tyr Gly Ser Arg His Leu Ala Ala Lys Met Ala
    210                 215                 220

Ser Thr Pro His Pro Pro Gly Ala Arg Gly Thr Ser Gln Leu His Gly
225                 230                 235                 240

Met Asp Leu Leu Val Leu Leu Asp Leu Ile Gly Ala Pro Asn Pro Thr
                245                 250                 255

Phe Pro Asn Phe Phe Pro Asn Ser Ala Arg Trp Phe Glu Arg Leu Gln
            260                 265                 270

Ala Ile Glu His Glu Leu His Glu Leu Gly Leu Leu Lys Asp His Ser
        275                 280                 285

Leu Glu Gly Arg Tyr Phe Gln Asn Tyr Ser Tyr Gly Gly Val Ile Gln
    290                 295                 300

Asp Asp His Ile Pro Phe Leu Arg Arg Gly Val Pro Val Leu His Leu
305                 310                 315                 320

Ile Pro Ser Pro Phe Pro Glu Val Trp His Thr Met Asp Asp Asn Glu
                325                 330                 335

Glu Asn Leu Asp Glu Ser Thr Ile Asp Asn Leu Asn Lys Ile Leu Gln
            340                 345                 350

Val Phe Val Leu Glu Tyr Leu His Leu
        355                 360


<210>  2
<211>  382
<212>  PRT
<213>  Homo sapiens

<400>  2

Met Arg Ser Gly Gly Arg Gly Arg Pro Arg Leu Arg Leu Gly Glu Arg
1               5                   10                  15

Gly Leu Met Glu Pro Leu Leu Pro Pro Lys Arg Arg Leu Leu Pro Arg
            20                  25                  30

Val Arg Leu Leu Pro Leu Leu Leu Ala Leu Ala Val Gly Ser Ala Phe
        35                  40                  45

Tyr Thr Ile Trp Ser Gly Trp His Arg Arg Thr Glu Glu Leu Pro Leu
    50                  55                  60
```

```
Gly Arg Glu Leu Arg Val Pro Leu Ile Gly Ser Leu Pro Glu Ala Arg
65                  70                  75                  80

Leu Arg Arg Val Val Gly Gln Leu Asp Pro Gln Arg Leu Trp Ser Thr
                85                  90                  95

Tyr Leu Arg Pro Leu Leu Val Val Arg Thr Pro Gly Ser Pro Gly Asn
            100                 105                 110

Leu Gln Val Arg Lys Phe Leu Glu Ala Thr Leu Arg Ser Leu Thr Ala
        115                 120                 125

Gly Trp His Val Glu Leu Asp Pro Phe Thr Ala Ser Thr Pro Leu Gly
    130                 135                 140

Pro Val Asp Phe Gly Asn Val Val Ala Thr Leu Asp Pro Arg Ala Ala
145                 150                 155                 160

Arg His Leu Thr Leu Ala Cys His Tyr Asp Ser Lys Leu Phe Pro Pro
                165                 170                 175

Gly Ser Thr Pro Phe Val Gly Ala Thr Asp Ser Ala Val Pro Cys Ala
            180                 185                 190

Leu Leu Leu Glu Leu Ala Gln Ala Leu Asp Leu Glu Leu Ser Arg Ala
        195                 200                 205

Lys Lys Gln Ala Ala Pro Val Thr Leu Gln Leu Leu Phe Leu Asp Gly
    210                 215                 220

Glu Glu Ala Leu Lys Glu Trp Gly Pro Lys Asp Ser Leu Tyr Gly Ser
225                 230                 235                 240

Arg His Leu Ala Gln Leu Met Glu Ser Ile Pro His Ser Pro Gly Pro
                245                 250                 255

Thr Arg Ile Gln Ala Ile Glu Leu Phe Met Leu Leu Asp Leu Leu Gly
            260                 265                 270

Ala Pro Asn Pro Thr Phe Tyr Ser His Phe Pro Arg Thr Val Arg Trp
        275                 280                 285

Phe His Arg Leu Arg Ser Ile Glu Lys Arg Leu His Arg Leu Asn Leu
    290                 295                 300

Leu Gln Ser His Pro Gln Glu Val Met Tyr Phe Gln Pro Gly Glu Pro
305                 310                 315                 320

Phe Gly Ser Val Glu Asp Asp His Ile Pro Phe Leu Arg Arg Gly Val
                325                 330                 335

Pro Val Leu His Leu Ile Ser Thr Pro Phe Pro Ala Val Trp His Thr
```

340 345 350

Pro Ala Asp Thr Glu Val Asn Leu His Pro Pro Thr Val His Asn Leu
355 360 365

Cys Arg Ile Leu Ala Val Phe Leu Ala Glu Tyr Leu Gly Leu
370 375 380

<210> 3
<211> 364
<212> PRT
<213> Homo sapiens

<400> 3

Met Glu Pro Leu Leu Pro Pro Lys Arg Arg Leu Leu Pro Arg Val Arg
1 5 10 15

Leu Leu Pro Leu Leu Leu Ala Leu Ala Val Gly Ser Ala Phe Tyr Thr
20 25 30

Ile Trp Ser Gly Trp His Arg Arg Thr Glu Glu Leu Pro Leu Gly Arg
35 40 45

Glu Leu Arg Val Pro Leu Ile Gly Ser Leu Pro Glu Ala Arg Leu Arg
50 55 60

Arg Val Val Gly Gln Leu Asp Pro Gln Arg Leu Trp Ser Thr Tyr Leu
65 70 75 80

Arg Pro Leu Leu Val Val Arg Thr Pro Gly Ser Pro Gly Asn Leu Gln
85 90 95

Val Arg Lys Phe Leu Glu Ala Thr Leu Arg Ser Leu Thr Ala Gly Trp
100 105 110

His Val Glu Leu Asp Pro Phe Thr Ala Ser Thr Pro Leu Gly Pro Val
115 120 125

Asp Phe Gly Asn Val Val Ala Thr Leu Asp Pro Arg Ala Ala Arg His
130 135 140

Leu Thr Leu Ala Cys His Tyr Asp Ser Lys Leu Phe Pro Pro Gly Ser
145 150 155 160

Thr Pro Phe Val Gly Ala Thr Asp Ser Ala Val Pro Cys Ala Leu Leu
165 170 175

Leu Glu Leu Ala Gln Ala Leu Asp Leu Glu Leu Ser Arg Ala Lys Lys
180 185 190

Gln Ala Ala Pro Val Thr Leu Gln Leu Leu Phe Leu Asp Gly Glu Glu
195 200 205

```
Ala Leu Lys Glu Trp Gly Pro Lys Asp Ser Leu Tyr Gly Ser Arg His
    210                 215                 220

Leu Ala Gln Leu Met Glu Ser Ile Pro His Ser Pro Gly Pro Thr Arg
225                 230                 235                 240

Ile Gln Ala Ile Glu Leu Phe Met Leu Leu Asp Leu Leu Gly Ala Pro
                245                 250                 255

Asn Pro Thr Phe Tyr Ser His Phe Pro Arg Thr Val Arg Trp Phe His
            260                 265                 270

Arg Leu Arg Ser Ile Glu Lys Arg Leu His Arg Leu Asn Leu Leu Gln
        275                 280                 285

Ser His Pro Gln Glu Val Met Tyr Phe Gln Pro Gly Glu Pro Phe Gly
    290                 295                 300

Ser Val Glu Asp Asp His Ile Pro Phe Leu Arg Arg Gly Val Pro Val
305                 310                 315                 320

Leu His Leu Ile Ser Thr Pro Phe Pro Ala Val Trp His Thr Pro Ala
                325                 330                 335

Asp Thr Glu Val Asn Leu His Pro Pro Thr Val His Asn Leu Cys Arg
            340                 345                 350

Ile Leu Ala Val Phe Leu Ala Glu Tyr Leu Gly Leu
        355                 360


<210>  4
<211>  481
<212>  PRT
<213>  Homo sapiens

<400>  4

Val Trp Tyr Arg Phe Gln Gly Lys Ala Ala Met Arg Ser Gly Gly Arg
1               5                   10                  15

Gly Arg Pro Arg Leu Arg Leu Gly Glu Arg Gly Leu Met Glu Pro Leu
            20                  25                  30

Leu Pro Pro Lys Arg Arg Leu Leu Pro Arg Val Arg Leu Leu Pro Leu
        35                  40                  45

Leu Leu Ala Leu Ala Val Gly Ser Ala Phe Tyr Thr Ile Trp Ser Gly
    50                  55                  60

Trp His Arg Arg Thr Glu Glu Leu Pro Leu Gly Arg Glu Leu Arg Val
65                  70                  75                  80

Pro Leu Ile Gly Ser Leu Pro Glu Ala Arg Leu Arg Arg Val Val Gly
```

```
                85                  90                  95

Gln Leu Asp Pro Gln Arg Leu Trp Ser Thr Tyr Leu Arg Pro Leu Leu
            100                 105                 110

Val Val Arg Thr Pro Gly Ser Pro Gly Asn Leu Gln Val Arg Lys Phe
        115                 120                 125

Leu Glu Ala Thr Leu Arg Ser Leu Thr Ala Gly Trp His Val Glu Leu
    130                 135                 140

Asp Pro Phe Thr Ala Ser Thr Pro Leu Gly Pro Val Asp Phe Gly Asn
145                 150                 155                 160

Val Val Ala Thr Leu Asp Pro Arg Ala Ala Arg His Leu Thr Leu Ala
                165                 170                 175

Cys His Tyr Asp Ser Lys Leu Phe Pro Pro Gly Ser Thr Pro Phe Val
            180                 185                 190

Gly Ala Thr Asp Ser Ala Val Pro Cys Ala Leu Leu Leu Glu Leu Ala
        195                 200                 205

Gln Ala Leu Asp Leu Glu Leu Ser Arg Ala Lys Lys Gln Ala Ala Pro
    210                 215                 220

Val Thr Leu Gln Leu Leu Phe Leu Asp Gly Glu Glu Ala Leu Lys Glu
225                 230                 235                 240

Trp Gly Pro Lys Asp Ser Leu Tyr Gly Ser Arg His Leu Ala Gln Leu
                245                 250                 255

Met Glu Ser Ile Pro His Ser Pro Gly Pro Thr Arg Ile Gln Ala Ile
            260                 265                 270

Glu Leu Phe Met Leu Leu Asp Leu Leu Gly Ala Pro Asn Pro Thr Phe
        275                 280                 285

Tyr Ser His Phe Pro Arg Thr Val Arg Trp Phe His Arg Leu Arg Ser
    290                 295                 300

Ile Glu Lys Arg Leu His Arg Leu Asn Leu Leu Gln Ser His Pro Gln
305                 310                 315                 320

Glu Val Met Tyr Phe Gln Pro Gly Glu Pro Phe Gly Ser Val Glu Asp
                325                 330                 335

Asp His Ile Pro Phe Leu Arg Arg Gly Val Pro Val Leu His Leu Ile
            340                 345                 350

Ser Thr Pro Phe Pro Ala Val Trp His Thr Pro Ala Asp Thr Glu Val
        355                 360                 365
```

```
Asn Leu His Pro Pro Thr Val His Asn Leu Cys Arg Ile Leu Ala Val
    370                 375                 380

Phe Leu Ala Glu Tyr Leu Gly Leu Arg Ala Trp Pro Met Thr Val Glu
385                 390                 395                 400

Arg Thr Val Arg Glu Lys Val Pro Ala Gly Ala Ser Glu Ala Gln Ala
                405                 410                 415

Gly Ser Ala Gly Val Leu Val Cys Pro Phe His Thr Phe Val Ser Leu
            420                 425                 430

Cys Tyr Asn Trp Lys Thr Phe Phe Leu Leu Ile Val Ser Ser Cys His
        435                 440                 445

Pro Ser Arg Thr Gly Lys Arg Pro Leu Trp Asp Asp Ser Gln Arg Asn
    450                 455                 460

Lys Asn Leu Leu Pro Pro Gln Arg Thr Leu Gly Pro Lys Val Cys Arg
465                 470                 475                 480

Asp
```

<210> 5
<211> 359
<212> PRT
<213> Homo sapiens

<400> 5

```
Ala Ala Met Arg Ser Gly Gly Arg Gly Arg Pro Arg Leu Arg Leu Gly
1               5                   10                  15

Glu Arg Gly Leu Met Glu Pro Leu Leu Pro Pro Lys Arg Arg Leu Leu
            20                  25                  30

Pro Arg Val Arg Leu Leu Pro Leu Leu Leu Ala Leu Ala Val Gly Ser
        35                  40                  45

Ala Phe Tyr Thr Ile Trp Ser Gly Trp His Arg Arg Thr Glu Glu Leu
    50                  55                  60

Pro Leu Gly Arg Glu Leu Arg Val Pro Leu Ile Gly Ser Leu Pro Glu
65                  70                  75                  80

Ala Arg Leu Arg Arg Val Val Gly Gln Leu Asp Pro Gln Arg Leu Trp
                85                  90                  95

Ser Thr Tyr Leu Arg Pro Leu Leu Val Val Arg Thr Pro Gly Ser Pro
            100                 105                 110
```

```
Gly Asn Leu Gln Val Arg Lys Ala Ala Pro Val Thr Leu Gln Leu Leu
        115                 120                 125

Phe Leu Asp Gly Glu Glu Ala Leu Lys Glu Trp Gly Pro Lys Asp Ser
    130                 135                 140

Leu Tyr Gly Ser Arg His Leu Ala Gln Leu Met Glu Ser Ile Pro His
145                 150                 155                 160

Ser Pro Gly Pro Thr Arg Ile Gln Ala Ile Glu Leu Phe Met Leu Leu
                165                 170                 175

Asp Leu Leu Gly Ala Pro Asn Pro Thr Phe Tyr Ser His Phe Pro Arg
            180                 185                 190

Thr Val Arg Trp Phe His Arg Leu Arg Ser Ile Glu Lys Arg Leu His
        195                 200                 205

Arg Leu Asn Leu Leu Gln Ser His Pro Gln Glu Val Met Tyr Phe Gln
    210                 215                 220

Pro Gly Glu Pro Phe Gly Ser Val Glu Asp Asp His Ile Pro Phe Leu
225                 230                 235                 240

Arg Arg Gly Val Pro Val Leu His Leu Ile Ser Thr Pro Phe Pro Ala
                245                 250                 255

Val Trp His Thr Pro Ala Asp Thr Glu Val Asn Leu His Pro Pro Thr
            260                 265                 270

Val His Asn Leu Cys Arg Ile Leu Ala Val Phe Leu Ala Glu Tyr Leu
        275                 280                 285

Gly Leu Arg Ala Trp Pro Met Thr Val Glu Arg Thr Val Arg Glu Lys
    290                 295                 300

Val Pro Ala Gly Ala Ser Glu Ala Gln Ala Gly Ser Ala Gly Val Leu
305                 310                 315                 320

Val Cys Pro Phe His Thr Phe Val Ser Leu Cys Tyr Asn Trp Lys Thr
                325                 330                 335

Phe Phe Leu Leu Ile Val Ser Ser Cys His Pro Ser Arg Thr Gly Lys
            340                 345                 350

Arg Pro Leu Trp Asp Asp Ser
        355
```

<210> 6
<211> 42
<212> PRT
<213> Homo sapiens

<400> 6

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
20 25 30

Gly Leu Met Val Gly Gly Val Val Ile Ala
35 40

<210> 7
<211> 40
<212> PRT
<213> Homo sapiens

<400> 7

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
20 25 30

Gly Leu Met Val Gly Gly Val Val
35 40

<210> 8
<211> 40
<212> PRT
<213> Homo sapiens

<400> 8

Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val
1 5 10 15

Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu
20 25 30

Met Val Gly Gly Val Val Ile Ala
35 40

<210> 9
<211> 38
<212> PRT
<213> Homo sapiens

<400> 9

Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val
1 5 10 15

Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu
20 25 30

Met Val Gly Gly Val Val
35

<210> 10
<211> 38
<212> PRT
<213> Homo sapiens

<400> 10

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
20 25 30

Gly Leu Met Val Gly Gly
35

<210> 11
<211> 36
<212> PRT
<213> Homo sapiens

<400> 11

Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val
1 5 10 15

Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu
20 25 30

Met Val Gly Gly
35

<210> 12
<211> 34
<212> PRT
<213> Homo sapiens

<400> 12

Glu Ala Ser Asn Cys Phe Ala Ile Arg His Phe Glu Asn Lys Phe Ala
1 5 10 15

Val Glu Thr Leu Ile Cys Ser Arg Thr Val Lys Lys Asn Ile Ile Glu
20 25 30

Glu Asn

<210> 13
<211> 34
<212> PRT
<213> Homo sapiens

<400> 13

Glu Ala Ser Asn Cys Phe Ala Ile Arg His Phe Glu Asn Lys Phe Ala
1 5 10 15

```
Val Glu Thr Leu Ile Cys Phe Asn Leu Phe Leu Asn Ser Gln Glu Lys
            20                  25                  30

His Tyr


<210>  14
<211>  76
<212>  PRT
<213>  Homo sapiens

<400>  14

Gln Pro Asp Ala Ile Asn Ala Pro Val Thr Cys Cys Tyr Asn Phe Thr
1               5                   10                  15

Asn Arg Lys Ile Ser Val Gln Arg Leu Ala Ser Tyr Arg Arg Ile Thr
            20                  25                  30

Ser Ser Lys Cys Pro Lys Glu Ala Val Ile Phe Lys Thr Ile Val Ala
        35                  40                  45

Lys Glu Ile Cys Ala Asp Pro Lys Gln Lys Trp Val Gln Asp Ser Met
    50                  55                  60

Asp His Leu Asp Lys Gln Thr Gln Thr Pro Lys Thr
65                  70                  75


<210>  15
<211>  76
<212>  PRT
<213>  Homo sapiens

<400>  15

Gln Pro Val Gly Ile Asn Thr Ser Thr Thr Cys Cys Tyr Arg Phe Ile
1               5                   10                  15

Asn Lys Lys Ile Pro Lys Gln Arg Leu Glu Ser Tyr Arg Arg Thr Thr
            20                  25                  30

Ser Ser His Cys Pro Arg Glu Ala Val Ile Phe Lys Thr Lys Leu Asp
        35                  40                  45

Lys Glu Ile Cys Ala Asp Pro Thr Gln Lys Trp Val Gln Asp Phe Met
    50                  55                  60

Lys His Leu Asp Lys Lys Thr Gln Thr Pro Lys Leu
65                  70                  75


<210>  16
<211>  76
<212>  PRT
<213>  Homo sapiens

<400>  16
```

```
Gln Pro Asp Ser Val Ser Ile Pro Ile Thr Cys Cys Phe Asn Val Ile
1               5                   10                  15

Asn Arg Lys Ile Pro Ile Gln Arg Leu Glu Ser Tyr Thr Arg Ile Thr
            20                  25                  30

Asn Ile Gln Cys Pro Lys Glu Ala Val Ile Phe Lys Thr Lys Arg Gly
        35                  40                  45

Lys Glu Val Cys Ala Asp Pro Lys Glu Arg Trp Val Arg Asp Ser Met
    50                  55                  60

Lys His Leu Asp Gln Ile Phe Gln Asn Leu Lys Pro
65                  70                  75
```

<210> 17
<211> 101
<212> PRT
<213> Mus musculus

<400> 17

```
Gln Ile Thr His Ala Thr Glu Thr Lys Glu Val Gln Ser Ser Leu Lys
1               5                   10                  15

Ala Gln Gln Gly Leu Glu Ile Glu Met Phe His Met Gly Phe Gln Asp
            20                  25                  30

Ser Ser Asp Cys Cys Leu Ser Tyr Asn Ser Arg Ile Gln Cys Ser Arg
        35                  40                  45

Phe Ile Gly Tyr Phe Pro Thr Ser Gly Gly Cys Thr Arg Pro Gly Ile
    50                  55                  60

Ile Phe Ile Ser Lys Arg Gly Phe Gln Val Cys Ala Asn Pro Ser Asp
65                  70                  75                  80

Arg Arg Val Gln Arg Cys Ile Glu Arg Leu Glu Gln Asn Ser Gln Pro
                85                  90                  95

Arg Thr Tyr Lys Gln
            100
```

<210> 18
<211> 75
<212> PRT
<213> Homo sapiens

<400> 18

```
Gln Pro Asp Ala Leu Asn Val Pro Ser Thr Cys Cys Phe Thr Phe Ser
1               5                   10                  15

Ser Lys Lys Ile Ser Leu Gln Arg Leu Lys Ser Tyr Val Ile Thr Thr
            20                  25                  30
```

Ser Arg Cys Pro Gln Lys Ala Val Ile Phe Arg Thr Lys Leu Gly Lys
35 40 45

Glu Ile Cys Ala Asp Pro Lys Glu Lys Trp Val Gln Asn Tyr Met Lys
50 55 60

His Leu Gly Arg Lys Ala His Thr Leu Lys Thr
65 70 75

<210> 19
<211> 92
<212> PRT
<213> Homo sapiens

<400> 19

Gln Phe Ile Asn Asp Ala Glu Thr Glu Leu Met Met Ser Lys Leu Pro
1 5 10 15

Leu Glu Asn Pro Val Val Leu Asn Ser Phe His Phe Ala Ala Asp Cys
20 25 30

Cys Thr Ser Tyr Ile Ser Gln Ser Ile Pro Cys Ser Leu Met Lys Ser
35 40 45

Tyr Phe Glu Thr Ser Ser Glu Cys Ser Lys Pro Gly Val Ile Phe Leu
50 55 60

Thr Lys Lys Gly Arg Gln Val Cys Ala Lys Pro Ser Gly Pro Gly Val
65 70 75 80

Gln Asp Cys Met Lys Lys Leu Lys Pro Tyr Ser Ile
85 90

<210> 20
<211> 97
<212> PRT
<213> Homo sapiens

<400> 20

Gln Pro Lys Val Pro Glu Trp Val Asn Thr Pro Ser Thr Cys Cys Leu
1 5 10 15

Lys Tyr Tyr Glu Lys Val Leu Pro Arg Arg Leu Val Val Gly Tyr Arg
20 25 30

Lys Ala Leu Asn Cys His Leu Pro Ala Ile Ile Phe Val Thr Lys Arg
35 40 45

Asn Arg Glu Val Cys Thr Asn Pro Asn Asp Asp Trp Val Gln Glu Tyr
50 55 60

Ile Lys Asp Pro Asn Leu Pro Leu Leu Pro Thr Arg Asn Leu Ser Thr

65 70 75 80

Val Lys Ile Ile Thr Ala Lys Asn Gly Gln Pro Gln Leu Leu Asn Ser
85 90 95

Gln

<210> 21
<211> 373
<212> PRT
<213> Homo sapiens

<400> 21

Gln His His Gly Val Thr Lys Cys Asn Ile Thr Cys Ser Lys Met Thr
1 5 10 15

Ser Lys Ile Pro Val Ala Leu Leu Ile His Tyr Gln Gln Asn Gln Ala
20 25 30

Ser Cys Gly Lys Arg Ala Ile Ile Leu Glu Thr Arg Gln His Arg Leu
35 40 45

Phe Cys Ala Asp Pro Lys Glu Gln Trp Val Lys Asp Ala Met Gln His
50 55 60

Leu Asp Arg Gln Ala Ala Ala Leu Thr Arg Asn Gly Gly Thr Phe Glu
65 70 75 80

Lys Gln Ile Gly Glu Val Lys Pro Arg Thr Thr Pro Ala Ala Gly Gly
85 90 95

Met Asp Glu Ser Val Val Leu Glu Pro Glu Ala Thr Gly Glu Ser Ser
100 105 110

Ser Leu Glu Pro Thr Pro Ser Ser Gln Glu Ala Gln Arg Ala Leu Gly
115 120 125

Thr Ser Pro Glu Leu Pro Thr Gly Val Thr Gly Ser Ser Gly Thr Arg
130 135 140

Leu Pro Pro Thr Pro Lys Ala Gln Asp Gly Gly Pro Val Gly Thr Glu
145 150 155 160

Leu Phe Arg Val Pro Pro Val Ser Thr Ala Ala Thr Trp Gln Ser Ser
165 170 175

Ala Pro His Gln Pro Gly Pro Ser Leu Trp Ala Glu Ala Lys Thr Ser
180 185 190

Glu Ala Pro Ser Thr Gln Asp Pro Ser Thr Gln Ala Ser Thr Ala Ser
195 200 205

```
Ser Pro Ala Pro Glu Glu Asn Ala Pro Ser Glu Gly Gln Arg Val Trp
    210                 215                 220

Gly Gln Gly Gln Ser Pro Arg Pro Glu Asn Ser Leu Glu Arg Glu Glu
225                 230                 235                 240

Met Gly Pro Val Pro Ala His Thr Asp Ala Phe Gln Asp Trp Gly Pro
                245                 250                 255

Gly Ser Met Ala His Val Ser Val Val Pro Val Ser Ser Glu Gly Thr
            260                 265                 270

Pro Ser Arg Glu Pro Val Ala Ser Gly Ser Trp Thr Pro Lys Ala Glu
        275                 280                 285

Glu Pro Ile His Ala Thr Met Asp Pro Gln Arg Leu Gly Val Leu Ile
    290                 295                 300

Thr Pro Val Pro Asp Ala Gln Ala Ala Thr Arg Arg Gln Ala Val Gly
305                 310                 315                 320

Leu Leu Ala Phe Leu Gly Leu Leu Phe Cys Leu Gly Val Ala Met Phe
                325                 330                 335

Thr Tyr Gln Ser Leu Gln Gly Cys Pro Arg Lys Met Ala Gly Glu Met
            340                 345                 350

Ala Glu Gly Leu Arg Tyr Ile Pro Arg Ser Cys Gly Ser Asn Ser Tyr
        355                 360                 365

Val Leu Val Pro Val
    370


<210>  22
<211>  127
<212>  PRT
<213>  Homo sapiens

<400>  22

Gln Gly Val Phe Glu Asp Cys Cys Leu Ala Tyr His Tyr Pro Ile Gly
1               5                   10                  15

Trp Ala Val Leu Arg Arg Ala Trp Thr Tyr Arg Ile Gln Glu Val Ser
            20                  25                  30

Gly Ser Cys Asn Leu Pro Ala Ala Ile Phe Tyr Leu Pro Lys Arg His
        35                  40                  45

Arg Lys Val Cys Gly Asn Pro Lys Ser Arg Glu Val Gln Arg Ala Met
    50                  55                  60

Lys Leu Leu Asp Ala Arg Asn Lys Val Phe Ala Lys Leu His His Asn
```

```
65                  70                  75                  80

Thr Gln Thr Phe Gln Ala Gly Pro His Ala Val Lys Lys Leu Ser Ser
                85                  90                  95

Gly Asn Ser Lys Leu Ser Ser Ser Lys Phe Ser Asn Pro Ile Ser Ser
            100                 105                 110

Ser Lys Arg Asn Val Ser Leu Leu Ile Ser Ala Asn Ser Gly Leu
        115                 120                 125
```